科研之友
微信
新浪微博
Facebook
分享链接
摘要
To investigate the safety and efficacy of limited vitrectomy with intravitreal bevacizumab, recombinant tissue plasminogen activator (rt-PA) and gas for displacement of submacular hemorrhage due to exudative age-related macular degeneration (AMD). %26lt;br%26gt;In this retrospective pilot study 11 eyes of 11 patients with submacular hemorrhage secondary to AMD were analyzed. %26lt;br%26gt;A limited 23 g-one-port pars plana vitrectomy was performed and 50 mu g rt-PA, 1.25 mg bevacizumab and about 1.5 mL of 100 % sulfur hexafluoride (SF6) were injected into the vitreous. The best and the final visual acuity and blood displacement from the fovea were evaluated postoperatively. %26lt;br%26gt;The best postoperative visual acuity (VA) was obtained at a median of 1 month after surgery (range 0.5-6 months) and demonstrated significantly better results than baseline VA for a short period of time (p = 0.04). No statistically significant improvement (p = 0.11) of the final visual acuity at a median of 3 months (range 0.5-6 months) compared to preoperative was found. Final visual acuity improved in 7 eyes, remained stable in 2 eyes and worsened in 2 eyes. Total pneumatic displacement of the submacular hemorrhage was obtained in 5 (46 %) eyes, partial displacement was shown in 2 (18 %) eyes. There was no displacement of the subretinal hemorrhage in 4 (36 %) eyes. %26lt;br%26gt;This surgical procedure seems to have no advantage over intravitreous injection of rt-PA and gas with or without complete vitrectomy concerning displacement rate of submacular hemorrhage and postoperative visual acuity.
- 出版日期2012-10
- 单位河北医科大学
